News

ALS Stem Cell Therapy Shows Safety and Efficacy in Early Clinical Trials

Biopharmaceutical company Neuralstem presented new and potentially promising results from its clinical investigations of NSI-566 — human spinal cord-derived neural stem cells for the treatment of conditions including amyotrophic lateral sclerosis (ALS) — at the recent Phacilitate Cell & Gene Therapy World conference in Washington, D.C. Karl Johe, the company’s chairman and chief scientific officer, reported that two clinical trials…

ALS, Gulf War Illness Caused by Toxic Exposures, Report Says

A report from the Boston University School of Public Health shows that Gulf War Illness is a result of exposure to pesticides and other toxins used in the Gulf War. The report also notes that in addition to Gulf War Illness, deployed Gulf War veterans suffer higher rates of stroke, brain cancer and…

New ALS Group’s Goal: Finding a New Treatment by 2020

Entrepreneur Kevin Gosnell announced the launch of ALS ONE – a partner organization of the ALS Association and ALS Finding a Cure that aims to bring world-leading experts in neurology and amyotrophic lateral sclerosis (ALS) care together to realize an ambitious goal: finding a new ALS treatment within four years.

Environmental Toxin a Possible Cause of Symptoms of ALS, Alzheimer’s Disease

Researchers at the Institute for EthnoMedicine and the University of Miami Brain Endowment Bank have discovered that chronic exposure to an environmental toxin has the potential to increase the risk for neurodegenerative illnesses such as ALS and Alzheimer’s disease. The research paper, “Dietary exposure to an environmental toxin triggers neurofibrillary tangles and…

Amylyx Appoints Nobel Laureate Walter Gilbert to Board of Directors

Amylyx Pharmaceuticals, a company developing a innovative therapeutic for amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), recently announced that former Biogen CEO Walter Gilbert, Ph.D and Nobel Laureate, will join Amylyx’s board of directors. “Dr. Gilbert brings an enormous breadth of experience as a scientist, biotech founder,…

In ALS Study, Essential Protein Seen as Promising New Theurapeutic Target

Researchers have identified an essential protein, Pur-alpha, for motor neuron cells’ mechanisms of defense against external stress and degeneration and also as a potential new therapeutic target for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease). The research paper, “Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates…

Key Players in Neuroinflammation Tied to ALS, Depression Highlighted

A recent review summarized the effects of immune system dysregulation and neuroinflammation in the regulation of critical pathways associated with depression and other brain disorders, including amyotrophic lateral sclerosis (ALS). The researchers specifically focused on extracellular vesicles (EVs) as potential biomarkers and drug delivery vehicles. The review, “Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles…